^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Bacteria replacement

    Related drugs:
    2ms
    Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (clinicaltrials.gov)
    P2, N=630, Suspended, Kibow Pharma | Trial completion date: Dec 2023 --> Dec 2025 | Recruiting --> Suspended | Trial primary completion date: Sep 2023 --> Sep 2025
    Trial completion date • Trial suspension • Trial primary completion date • Metastases
    2ms
    Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study (clinicaltrials.gov)
    P2/3, N=600, Suspended, Kibow Pharma | Trial completion date: Mar 2024 --> Mar 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial suspension • Trial primary completion date
    5ms
    MCGRAW: Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1, N=14, Completed, Parker Institute for Cancer Immunotherapy | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • SER-401
    7ms
    A Study of MRx-4DP0004 in Asthma (clinicaltrials.gov)
    P1, N=34, Terminated, 4D pharma plc | Phase classification: P1/2 --> P1
    Phase classification
    |
    IL6 (Interleukin 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • IL1B (Interleukin 1, beta) • TSLP (Thymic Stromal Lymphopoietin) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    1year
    Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study (clinicaltrials.gov)
    P2/3, N=600, Recruiting, Kibow Pharma | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    over3years
    Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1b, N=14, Active, not recruiting, Parker Institute for Cancer Immunotherapy | Trial primary completion date: Feb 2021 --> Jan 2022 | Trial completion date: Feb 2022 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • SER-401
    almost4years
    Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1b, N=14, Active, not recruiting, Parker Institute for Cancer Immunotherapy | Recruiting --> Active, not recruiting | N=30 --> 14
    Clinical • Enrollment closed • Enrollment change • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • SER-401